Global First Prescription of Aizeli® (Relafusp Alpha Injection) Filled at JD Health, Offering Dual-Targeted Therapy for Advanced Gastric Cancer Patients

Recently, Relafup Alfa Injection (trade name: Aizeli), a Class 1 innovative drug independently developed by Hengrui Pharma^®) The world’s first prescription was issued at the Suzhou Affiliated Hospital of Soochow University Store of JD Grand Pharmacy Chain (Jiangsu) Co., Ltd. Reilaifu Pu α Injection is the world’s first approved anti-PD-L1/TGF-βRII bispecific antibody fusion protein, offering a novel treatment option for patients with advanced gastric cancer. As the “first stop for the nationwide online launch of new specialty drugs,” JD Health will continue to leverage its “super pharmaceutical supply chain” capabilities to help more breakthrough therapies reach patients at the earliest opportunity, thereby promoting access to innovative treatments.

China has a high proportion of patients with advanced gastric cancer, posing a severe challenge to disease diagnosis and treatment. Immunotherapy is currently one of the standard first-line treatments for advanced gastric cancer; however, immune checkpoint inhibitor monotherapy offers limited improvement in long-term survival, particularly showing poor efficacy in refractory populations such as those with gastric cancer liver metastases. There is an urgent need for innovative therapeutic regimens.

Aizerly^®It is the world’s first approved PD-L1/TGF-βRII bispecific antibody fusion protein. By simultaneously blocking PD-L1 signaling and neutralizing the TGF-β pathway, it synergistically overcomes immunosuppression within the tumor microenvironment and activates the body’s anti-tumor immune response. Based on robust data from the Phase III RELIGHT study, the drug demonstrated significant survival benefits in patients with PD-L1-positive advanced gastric cancer, particularly among those with liver metastases, resulting in a significant extension of median overall survival and offering new therapeutic hope for patients.

The successful execution of this inaugural transaction represents a significant practice in the collaborative promotion of the innovative “Healthcare + Pharmaceuticals + Services” closed-loop model by JD Health and Hengrui Pharma. Hengrui Pharma is a leading domestic enterprise in innovative drugs, Aizeli^®The market launch further enriches its portfolio of innovative oncology drugs. JD Health, leveraging its nationwide DTP pharmacy network, team of professional pharmacists, and integrated online-offline service system, is committed to providing patients with end-to-end management—from prescription review and medication guidance to long-term follow-up—ensuring the safe, convenient, and efficient implementation of innovative therapies.

A representative from JD Pharmacy’s offline stores stated, “We will fully leverage the geographic coverage advantages of our physical locations and the professional services provided by our pharmacists to ensure that patients not only gain immediate access to breakthrough therapeutic drugs but also receive comprehensive support ranging from medication guidance to long-term health management.”

Looking ahead, JD Health will leverage this collaboration to deepen its engagement with innovative pharmaceutical companies, enhance the accessibility of cutting-edge anti-tumor drugs, contribute to advancing China’s cancer prevention and treatment capabilities, and benefit more patients.